<DOC>
	<DOCNO>NCT03024580</DOCNO>
	<brief_summary>This pilot trial evaluate vivo megestrol acetate ( MA ) modulation steroidal receptor advance breast cancer .</brief_summary>
	<brief_title>A Study Evaluating Megestrol Acetate Modulation Hormone Receptor Positive Advanced Breast Cancer</brief_title>
	<detailed_description>Progesterone receptor ( PR ) expression consider biomarker oestrogen receptor-α ( ERα ) activity . This longstanding relationship recently challenge instead merely ERα-induced gene target , PR may critical determinant ERα activity . The functional significance steroid receptor crosstalk regulation gene expression program associate low tumorigenicity ; hence , good disease outcome . Genomic alteration PR genomic locus seem relatively common mechanism reduction PR expression , may consequently lead altered ERα chromatin bind target gene expression pattern increase breast tumorigenicity confers poor clinical outcome . This ERα-PR crosstalk may directly influence many variable , include relative receptor level hormonal milieu . ER-positive advanced breast cancer heterogeneous group diseases considerable variability outcome range treatment . Prior response predict likelihood subsequent benefit another endocrine agent take account treatment decision process assess whether prescribe subsequent endocrine therapy . Despite enormous progress make regard elucidation breast cancer subgroup molecular driver , information come primary tumor . MA lack cross-resistance active acquire resistance potent AI . This pilot trial evaluate vivo MA modulation steroidal receptor advance breast cancer .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Megestrol</mesh_term>
	<mesh_term>Megestrol Acetate</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>Metastatic breast cancer ER and/or PR positive ( primary tumor ) Metastatic site amenable biopsy Platelet count 100,000 / mm3 Renal hepatic impairment Coagulation disorder</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Megestrol Acetate</keyword>
	<keyword>Steroid , Receptors</keyword>
</DOC>